Inflammatory bowel disease (IBD) JAK inhibitor demand — the tofacitinib (Xeljanz, Pfizer) ulcerative colitis (UC) approval and upadacitinib (Rinvoq, AbbVie) UC/Crohn's disease (CD) approvals creating oral targeted therapy for biologic-inadequate responders and anti-TNF primary non-responders representing the most rapidly expanding gastroenterology indication in the global JAK inhibitors...